Navigation Links
Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
Date:10/23/2008

PRINCETON, N.J., Oct. 23 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the BIO Investor Forum in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, October 29, 2008 at 1:45 PM PDT in the Marina Room of the Palace Hotel.

The company is also pleased to announce that Dr. Arthur Louie, chief medical officer, has been invited to participate in a therapeutic workshop titled, "Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon." The workshop will be held on Thursday, October 30, 2008 at 9:30 AM PDT in the Twin Peak South Room of the Palace Hotel.

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with advanced leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
3. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
7. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
8. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)... Ames, Iowa (PRWEB) , ... December 08, 2016 , ... ... of asynchronous approvals for biotech crops. The authors focus on the economic effects in ... the global approval of new biotech crops and the resultant risk of low level ...
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   ... identification and object recognition technologies, today released ... for fingerprint recognition solutions that run on ... fingerprint template using less than 128KB of ... compact devices that have limited on-board resources, ...
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):